Prognosis of acute-on-chronic liver failure patients treated with artificial liver support system.

Aim: To establish a new model for predicting survival in acute-on-chronic liver failure (ACLF) patients treated with an artificial liver support system.

Methods: One hundred and eighty-one ACLF patients who were admitted to the hospital from January 1, 2012 to December 31, 2014 and were treated with an artificial liver support system were enrolled in this retrospective study, including a derivation cohort (n = 113) and a validation cohort (n = 68). Laboratory parameters at baseline were analyzed and correlated with clinical outcome.

[Inhibition of quercetin on liver fibrosis due to Schistosoma japonicum infection and on the expression of immediate early gene and metalloproteinase 1 inhibitor in liver tissue of mice].

Quercetin and praziquantel were used to treat mice with hepatic fibrosis due to Schistosoma japonicum infection. Quercetin treatment obviously relieved the degree of hepatic fibrosis, significantly reduced the expression of immediate early gene, tissue inhibitor of metalloproteinase 1 (TIMP 1), types I and III collagen compared to the control. The expression of c-jun mRNA, type I and type III collagen were reduced significantly compared to the group treated with praziquantel, whereas no difference in the expression of c-fos mRNA and TIMP1 between the two groups, indicating that quercetin may have better effect on schistosomal liver fibrosis than praziquantel in the long term.